Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Cardiology

Standard Treatment and Medications

At a Glance

Autoimmune myocarditis is treated with medicines and devices that support the heart plus carefully selected drugs that calm the immune system. Corticosteroids are central for some forms; severe or resistant cases may need hospital care and additional therapies.

Treating immune-mediated myocarditis is a two-track process. First, your doctors must support your heart’s physical function (managing its rhythm and pumping strength). Second, they must address the “root cause” by using immunosuppression to stop your immune system from attacking your heart [1][2].

Supporting Heart Function

Not everyone needs these, but treatment for reduced pumping function, fluid overload, or rhythm problems is a foundational step:

  • Heart Failure Medicines: Drugs like beta-blockers or diuretics to reduce fluid overload.
  • Rhythm Monitoring: Pacemakers, defibrillators, or anti-arrhythmics if the electrical system is failing.
  • Mechanical Support: Fulminant disease may require intensive heart-failure care, mechanical support, or transplant evaluation.

The Role of Corticosteroids

For selected immune-mediated forms—such as ICI-associated, giant-cell, eosinophilic, or systemic autoimmune disease—high-dose corticosteroids (such as methylprednisolone or prednisone) are important starting points. Routine immunosuppression is not appropriate for every suspected myocarditis, however, and can worsen an infection [3][4].

  • Administration: In severe cases, you may receive “pulse” doses—high amounts given intravenously (IV) for several days [5][6].
  • The Taper: Once your heart markers stabilize, your doctor will slowly “taper” the dose. Never stop prescribed immunosuppression abruptly without the treating team, as dropping the dose too quickly can cause a dangerous flare-up [7][8].

Specific Protocol for ICI-Associated Myocarditis

If your myocarditis was strongly suspected to be triggered by an Immune Checkpoint Inhibitor (ICI) for cancer treatment, the protocol is more urgent [9]:

  1. Immediate Action: The cancer drug is usually held immediately. Permanent discontinuation is commonly recommended for significant cases, with decisions made jointly by an oncology and cardio-oncology team [9][10].
  2. Rapid Steroids: Guidelines recommend prompt corticosteroid treatment, often in the hospital. The specific dose and route depend on hemodynamic status, conduction disease, and coexisting myositis or myasthenia [4][5][6].
  3. Monitoring: Because this subtype often involves other muscles, doctors will monitor you for signs of myositis or myasthenia gravis [11][12].

Escalation Therapies for Refractory Cases

Sometimes, steroids alone aren’t enough. If your heart markers remain high or your condition worsens, your team may consider escalation therapies. These escalation decisions are individualized and urgent, depending on hemodynamics, rhythm, and imaging [13][14]:

  • Abatacept: A targeted drug sometimes used off-label when ICI-myocarditis doesn’t respond to steroids [15][16].
  • Mycophenolate Mofetil: Often used as a long-term “steroid-sparing” agent [17][18].
  • IVIG or Plasma Exchange: IVIG is context-dependent, and plasma exchange filters the blood, though evidence for these in refractory ICI myocarditis is limited and heterogeneous [17][19].

Managing the Harms of High-Dose Steroids

While steroids are life-saving, your care team will direct specific preventative measures for these potential harms [20]:

Risk Area Clinician-Directed Monitoring & Prevention
Infection Clinicians may prescribe prophylactic antibiotics (e.g., for Pneumocystis) in selected patients receiving prolonged/combined immunosuppression. Monitor closely for fever [20][21].
Blood Sugar Steroids can cause spikes in blood sugar, requiring glucose monitoring [11].
Bone Health Clinicians may recommend calcium, Vitamin D, or specific bone-protecting medications based on dose and duration [11].
Stomach Issues Gastroprotection (like a PPI) depends on your specific GI-bleeding risk and other medications [11].
Mental Health High doses can cause anxiety, mood swings, or severe insomnia [11].

Treatment is a marathon, not a sprint, and your team will use repeat imaging and monitoring to guide your therapy [7][22].

Common questions in this guide

Are corticosteroids always used to treat autoimmune myocarditis?
No. High-dose corticosteroids are important for selected immune-mediated forms, including ICI-associated, giant-cell, eosinophilic, or systemic autoimmune myocarditis. Doctors may assess severity and rule out active infection before starting immunosuppression because it can worsen an infection.
What medicines support the heart during autoimmune myocarditis?
Treatment may include beta-blockers or diuretics for reduced pumping function or fluid overload. Rhythm medicines, pacemakers, defibrillators, mechanical support, or transplant evaluation may be needed when electrical or pumping problems are severe.
How is ICI-associated myocarditis treated?
The immune checkpoint inhibitor is usually held immediately, and significant cases commonly lead to permanent discontinuation after oncology and cardio-oncology review. Prompt corticosteroids and hospital monitoring may be needed, along with evaluation for myositis or myasthenia gravis.
Why must corticosteroids be tapered slowly?
Once heart markers stabilize, clinicians gradually lower the corticosteroid dose. Stopping suddenly or reducing it too quickly can trigger a dangerous flare, so all dose changes should be directed by the treating team.
What happens if steroids do not control autoimmune myocarditis?
If heart markers remain high or the condition worsens, the care team may consider escalation therapy such as abatacept, mycophenolate mofetil, IVIG, or plasma exchange. These decisions depend on circulation, heart rhythm, imaging, and the suspected cause, and some options are used off-label or have limited evidence.
How are high-dose steroid side effects monitored?
Your team may monitor for infection, blood sugar changes, bone loss, stomach problems, anxiety, mood changes, and insomnia. Depending on your medicines and treatment duration, they may recommend infection prevention, calcium or vitamin D, bone-protecting treatment, stomach protection, or glucose checks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific subtype of myocarditis am I being treated for, and was a biopsy or viral testing used to rule out an active infection before starting immunosuppressants?
  2. 2.If I have ICI-associated myocarditis, have we officially halted my cancer therapy, and what are the criteria for potentially restarting it in the future?
  3. 3.What is my target steroid dose, and how frequently will we be checking my troponin levels to decide when it's safe to start 'tapering' or lowering the dose?
  4. 4.At what point would we decide that steroids aren't enough and move to 'escalation' therapies like mycophenolate or abatacept?
  5. 5.What is our plan for preventing common steroid side effects, such as infections, bone loss, or high blood sugar?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Evolution in the Diagnosis and Treatment of Myocarditis in Recent Years: State of the Art.

    Campodonico J, Lauri C, Pezzuto B, et al.

    Journal of clinical medicine 2025; (14(21)) doi:10.3390/jcm14217661.

    PMID: 41227056
  2. 2

    Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis.

    Frustaci A, Letizia C, Alfarano M, et al.

    Biomedicines 2024; (12(7)) doi:10.3390/biomedicines12071565.

    PMID: 39062138
  3. 3

    Outcomes of Mechanical Circulatory Support for Giant Cell Myocarditis: A Systematic Review.

    Patel PM, Saxena A, Wood CT, et al.

    Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123905.

    PMID: 33271929
  4. 4

    Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.

    Wang Y, Li S, Shi H, et al.

    Cardiovascular diagnosis and therapy 2024; (14(4)):679-697 doi:10.21037/cdt-24-114.

    PMID: 39263485
  5. 5

    Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review.

    Man X, Wang H, Chen C, et al.

    Frontiers in immunology 2025; (16()):1455347 doi:10.3389/fimmu.2025.1455347.

    PMID: 40013153
  6. 6

    Immune-Related Fulminant Myocarditis Revealed Using Myocardial Histopathology at Autopsy in the Treatment of Advanced Renal Cell Carcinoma: A Case Report.

    Hayashi Y, Kawasaki Y, Katayama H, et al.

    Case reports in oncology 2025; (18(1)):738-743 doi:10.1159/000546288.

    PMID: 40519645
  7. 7

    Efficacy and safety of Songjiao Dihuang Tang decoction for the dynamic/adaptive treatment of immune checkpoint inhibitor-associated myocarditis: study protocol and statistical analysis plan for a stop&go, multicentre, randomized, parallel-controlled, double-blind, superiority clinical trial.

    Long J, Zheng J, Jin Z, et al.

    Frontiers in pharmacology 2026; (17()):1797368 doi:10.3389/fphar.2026.1797368.

    PMID: 42206175
  8. 8

    A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma.

    Li X, Feng Q, Yu Y, et al.

    Immunotherapy 2025; (17(17-18)):1241-1247 doi:10.1080/1750743X.2026.2619654.

    PMID: 41567119
  9. 9

    Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.

    Mauriello A, Correra A, Maratea AC, et al.

    Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020814.

    PMID: 41598751
  10. 10

    Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.

    Frascaro F, Bianchi N, Sanguettoli F, et al.

    Journal of clinical medicine 2023; (12(24)) doi:10.3390/jcm12247737.

    PMID: 38137806
  11. 11

    Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.

    Lu M, Muhetaer A, Su C, et al.

    Frontiers in immunology 2025; (16()):1671964 doi:10.3389/fimmu.2025.1671964.

    PMID: 41394836
  12. 12

    Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management.

    Becker RC

    Journal of thrombosis and thrombolysis 2025; (58(8)):1021-1044 doi:10.1007/s11239-025-03146-7.

    PMID: 40673965
  13. 13

    Corticosteroid-resistant immune-related adverse events: a systematic review.

    Daetwyler E, Wallrabenstein T, König D, et al.

    Journal for immunotherapy of cancer 2024; (12(1)) doi:10.1136/jitc-2023-007409.

    PMID: 38233099
  14. 14

    Fulminant Immune Checkpoint Inhibitor-Induced Myocarditis and Complete Heart Block in Advanced Melanoma: A Case Report.

    Alhayek B, Malone X, Rashid MA, et al.

    Cureus 2025; (17(11)):e98075 doi:10.7759/cureus.98075.

    PMID: 41473611
  15. 15

    Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.

    Salem JE, Bretagne M, Abbar B, et al.

    Cancer discovery 2023; (13(5)):1100-1115 doi:10.1158/2159-8290.CD-22-1180.

    PMID: 36815259
  16. 16

    Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design.

    Salem JE, Ederhy S, Belin L, et al.

    Archives of cardiovascular diseases 2025; (118(2)):106-115 doi:10.1016/j.acvd.2024.12.005.

    PMID: 39743436
  17. 17

    Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.

    Mir H, Alhussein M, Alrashidi S, et al.

    The Canadian journal of cardiology 2018; (34(8)):1059-1068 doi:10.1016/j.cjca.2018.03.012.

    PMID: 29980467
  18. 18

    Therapeutic strategies for virus-negative myocarditis: a comprehensive review.

    De Luca G, Campochiaro C, Sartorelli S, et al.

    European journal of internal medicine 2020; (77()):9-17 doi:10.1016/j.ejim.2020.04.050.

    PMID: 32402564
  19. 19

    Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy-case report.

    Schiopu SRI, Käsmann L, Schönermarck U, et al.

    Translational lung cancer research 2021; (10(2)):1039-1046 doi:10.21037/tlcr-20-1095.

    PMID: 33718042
  20. 20

    Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study.

    Caforio ALP, Giordani AS, Baritussio A, et al.

    European journal of heart failure 2024; (26(5)):1175-1185 doi:10.1002/ejhf.3220.

    PMID: 38629741
  21. 21

    Diagnostic and Therapeutic Options in Myocarditis and Inflammatory Cardiomyopathy.

    Schultheiss HP, Escher F, Aleshcheva G, et al.

    Biomedicines 2026; (14(3)) doi:10.3390/biomedicines14030691.

    PMID: 41898335
  22. 22

    Smoldering myocarditis following immune checkpoint blockade.

    Norwood TG, Westbrook BC, Johnson DB, et al.

    Journal for immunotherapy of cancer 2017; (5(1)):91 doi:10.1186/s40425-017-0296-4.

    PMID: 29157297

This page explains treatment options for autoimmune myocarditis for informational purposes only and does not replace medical advice. Your cardiology and treating teams must decide which medicines, monitoring, or escalation therapies are safe for you.

Get notified when new evidence is published on Autoimmune myocarditis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.